Table 5.
Summary of collagen-based strategies in neural tissue engineering applications. (NA: Not applicable).
| Approach | Collagen-based formula | Crosslinking method | Cell type | Cell density | Cell viability | Application | Ref. |
|---|---|---|---|---|---|---|---|
| Drop-on-demand bioprinting | Agarose and collagen I | – | 1. MSCs 2. HUVECs 3. Human bone marrow-derived epithelial neuroblastoma immortalized cells |
1. MSCs: 1 × 106 cells mL−1 2. HUVECs: 3 × 106 cells mL−1 3. Neuroblastoma cells: 1 × 106 cells mL−1 |
NA | Cancer modeling | [175] |
| Electrohydrodynamic jet printing | Collagen I and fibrin | EDC, NHS, CaCl2 and thrombin | NSPCs | 3 × 105 cells mL−1 | NA | SCI repair | [176] |
| Extrusion-based bioprinting | Collagen I, heparin sulfate, and basic fibroblast growth factor | UV cross-linking | Embryonic NSCs | NA | In vivo analysis | SCI repair | [41] |
| Collagen and silk fibroin | Solidification | Rat NSCs | 1 × 107 cells mL−1 | NA | SCI repair | [136] | |
| Hydrogel injection | HA/heparin/collagen | Polyethylene glycol diacrylate | ES-derived NPCs | 1.4 × 107 cells mL−1 | NA | Stroke recovery | [177] |
| Collagen I sponge | – | Rat 14-day-old-embryo brain-derived NSCs | 1 × 105 cells mL−1 | NA | Rat cerebral ischemia | [178] | |
| Collagen I | 4S-StarPEG | MSCs | 1 × 107 cells mL−1 | >90% | Brain cell graft platform | [96] | |
| Microsphere | The porcine skin-derived collagen solution | Water-soluble carbodiimide | HUVECs | – | Capillary formation | Sustained release of VEGF | [144] |
| Collagen I | EDC | 1. OPCs 2. DRG |
1. 1.5 × 104 cells/well 2. NA |
∼90% | Neurite myelination | [93] | |
| Electrospinning | PCL/Collagen | – | 1. DRG explants 2. SCs |
NA | ∼90% | Nerve implants | [179] |
| PCL/Collagen | – | 1. Astrocytes 2. Human astrocytoma cell line |
NA | NA | CNS repair | [180] | |
| Tethered conduit | Collagen I | Thermal | 1. Human HUVECs 2. SCs |
1. 4 × 106 cells mL−1 2. 5 × 105 cells mL−1 |
NA | PNI repair | [181] |